Clinical Trials
53 trialsNCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT03040999 2026-02-04
KEYNOTE-412
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04504942 2026-01-23
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
Phase 2 Completed
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT03724890 2025-04-10
Study of Avelumab-M3814 Combinations
EMD Serono
Phase 1 Completed
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT04866017 2024-10-31
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
NCT03250299 2024-06-24
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
Phase 1 Terminated
NCT02383498 2024-05-20
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
NantCell, Inc.
Phase 2 Completed
NCT03165994 2024-05-02
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
Phase 2 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT04551950 2024-03-08
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Phase 1 Completed
NCT02567799 2024-01-25
NSCLC
Humanetics Corporation
Phase 1/2 Completed
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT03770689 2023-03-21
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
EMD Serono
Phase 1/2 Completed
NCT02990468 2023-03-15
BMX-HN
BioMimetix JV, LLC
Phase 1/2 Completed
NCT01265849 2022-08-19
IT-MATTERS
CEL-SCI Corporation
Phase 3 Completed
NCT00573131 2022-06-22
Efficacy and Safety of OncoGelā¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Boston Scientific Corporation
Phase 2 Terminated
NCT03349710 2021-08-09
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT02266147 2020-09-04
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Dynavax Technologies Corporation
Phase 1/2 Terminated
NCT01017549 2020-08-13
Post Market Study Using the Xoft Axxent System
Xoft, Inc.
Phase NA Completed
NCT00402116 2020-08-06
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Eli Lilly and Company
Phase 1/2 Completed
NCT01390948 2020-08-06
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Hoffmann-La Roche
Phase 2 Completed
NCT02412371 2020-07-22
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 1/2 Terminated
NCT01790503 2020-06-30
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Daiichi Sankyo
Phase 1/2 Completed
NCT01289210 2019-09-25
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Celgene
Phase 1/2 Terminated
NCT00977431 2019-02-18
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
Boehringer Ingelheim
Phase 1 Completed
NCT01496131 2018-03-09
Tecemotide (L-BLP25) in Prostate Cancer
EMD Serono
Phase 2 Completed
NCT00943826 2017-09-25
A Study of Bevacizumab (AvastinĀ®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT00626639 2017-06-21
A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy
Swedish Orphan Biovitrum
Phase 1/2 Completed
NCT00686725 2017-06-14
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00266812 2017-06-08
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00684567 2017-06-07
Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00094861 2017-03-14
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Swedish Orphan Biovitrum
Phase 2 Completed
NCT00813943 2017-01-30
CORE
EMD Serono
Phase 2 Completed
NCT00527111 2016-11-03
Pre-op Rectal ChemoRad +/- Cetuximab
US Oncology Research
Phase 2 Completed
NCT00101582 2016-09-27
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Swedish Orphan Biovitrum
Phase 3 Completed
NCT00704808 2015-09-09
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Merck Sharp & Dohme LLC
Completed
NCT00725010 2015-09-09
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
Merck Sharp & Dohme LLC
Completed
NCT01227707 2015-08-17
A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00387127 2015-06-25
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00723827 2015-01-30
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Merck Sharp & Dohme LLC
Completed
NCT00689221 2014-11-04
CENTRIC
EMD Serono
Phase 3 Completed
NCT00529100 2013-07-09
Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00482014 2012-11-27
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00401401 2011-12-23
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Genmab
Phase 1/2 Terminated
NCT00460551 2011-12-06
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
Genmab
Phase 2 Terminated
NCT00371566 2010-04-06
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed